GSK asks for results from Exelixis cancer drug

08/23/2007 | Bloomberg

GlaxoSmithKline has requested preliminary study results from Exelixis for the experimental cancer drug XL880. Exelixis could receive a $70 million milestone payment if GSK continues to develop the drug, one analyst said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL